Feasibility of a Microarray-Based Point-of-Care <i>CYP2C19</i> Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity

<table>Result from the VerifyNow P2Y12 assay according to CYP2C19 metabolizer statuses. Data are shown as mean. The denotations are PRY: P2Y12 reaction units; UM: ultrarapid; EM: extensive; IM: intermediate; and PM: poor metabolizer.</table>

BioMed Research International

fig1

Figure 1

Figure 1: Feasibility of a Microarray-Based Point-of-Care <i>CYP2C19</i> Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity 

BioMed Research International

Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity

Figure 1